Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors

Honda, Yoshihiro; Takigawa, Nagio; Fushimi, Soichiro; Ochi, Nobuaki; Kubo, Toshio; Ozaki, Saeko; Tanimoto, Mitsune; Kiura, Katsuyuki

doi:10.1016/j.lungcan.2012.07.003

Cited by 9 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the possibility of intra-tumor heterogeneity has also been reported. 30,31 In these papers, the heterogeneity pattern was the combination of subclones with and without EGFR mutations. The present data are also comparable with these results.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Tomonaga

Nakamura

Yamaguchi

et al. 2013

Clinical Lung Cancer

View full text Add to dashboard Cite

2 Micro abstractIntra-tumor heterogeneity of epidermal growth factor receptor (EGFR) mutations in patients with mixed-type lung adenocarcinoma was analyzed according to histological patterns. Intra-tumor heterogeneity of EGFR mutations was detected in 9 of 38 tumors, and there was a significant correlation between heterogeneity of EGFR mutations and smoking history (P<0.043). Clinical Practice Points• EGFR mutations are factors predictive of response to EGFR-TKI treatment. However, lung cancer is thought to be the result of the accumulation of genetic alterations over a long course of exposure to a carcinogen, and the existence of intra-tumor heterogeneity of EGFR mutations remains unclear. Thus, the existence of intra-tumor heterogeneity was analyzed in patients with mixed-type lung adenocarcinoma according to histological patterns.• Intra-tumor heterogeneity of EGFR mutations was detected in 9 of 38 tumors, and a significant correlation between heterogeneity of EGFR 3 mutations and smoking history was found.• Response to EGFR-TKIs might be partial and insufficient in tumors having intra-tumor heterogeneity of EGFR mutations. New treatment strategies for patients with lung adenocarcinoma harboring heterogeneous EGFR mutations are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Tomonaga

Nakamura

Yamaguchi

et al. 2013

Clinical Lung Cancer

View full text Add to dashboard Cite

show abstract

“…With the extensive application of EGFR-TKIs, different response rates have been observed between first-line EGFR-TKIs and non-first-line EGFR-TKIs in patients with initial EGFR-positive mutations [5] [15]. In 2012, Honda et al reported the disappearance of an activated EGFR mutation in a female patient after extensive treatment with cytotoxic drugs [7].…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, some clinical studies have demonstrated increased serum EGFR mutation detection [5] [6]. In 2012, Honda et al [7] reported a Japanese woman with an initial EGFR mutation (L747-T751 deletion in exon 19) that disappeared after chemotherapy. The same year, an oncological study by Bai et al reported that chemotherapy may reduce the frequency of EGFR mutations in NSCLC patients [8].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

Shi¹,

Huang²,

Chen³

et al. 2017

OJGen

View full text Add to dashboard Cite

Background: Emerging evidence indicates that chemotherapy for lung cancer may alter EGFR mutation status. However, whether chemotherapy as a firstline treatment may increase or reduce the frequency of EGFR mutations in NSCLC remains uncertain. Therefore, we conducted a meta-analysis to evaluate whether chemotherapy leads to altered EGFR mutation status. Methods: A systematic literature search was performed using the PubMed, OVID, Science Direct, Cochrane Library, and CNKI databases for studies on pre-and post-chemotherapy EGFR mutation status. Relevant studies documenting perichemotherapy EGFR mutation ratios were included. Analyses of pooled odds ratios (OR) were performed. Results: Six studies involving 656 patients were included in this meta-analysis. It was found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 -3.56; p < 0.0001). No significant differences in EGFR mutation alterations were observed in terms of gender, smoking history, EGFR loci, or chemotherapy response in NSCLC patients. Conclusions: Chemotherapy may contribute to altered EGFR status. NSCLC

show abstract

“…In addition, studies comparing EGFR mutation status of biopsies and resection specimens revealed no discrepancies (table 2) [26][27][28]. This suggests that, in some NSCLCs heterogeneous for EGFR mutation [17,29,30], the number of tumour cells showing different mutational patterns in the primary tumour is very small and, thus, easily obscured by the predominant population and not detectable with usual methods. However, this intra-tumoural heterogeneity of EGFR mutations might partially account for the discrepancies in clinical response to EGFR-TKIs in EGFR-mutated patients and for cases with unexplained primary and secondary resistance [28,31,32].…”

Section: The Selection Of Biopsy Sitementioning

confidence: 90%

“…The genetic profiles of metastatic tumours might evolve or be clonally selected when metastasis occurs, and the time interval between primary tumour and metastasis is sufficiently long for outgrowth of heterogeneous subpopulations. In addition, chemotherapy or TKI therapy may affect EGFR mutation status by changing the overall frequency of EGFR mutant clones after drug treatment [19,29]. Therefore, in a small subset of patients, primary tumours may not be representative of the EGFR mutation status of the metastatic tumours.…”

Section: The Selection Of Biopsy Sitementioning

confidence: 99%

Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?

Kim

Tsao

2014

Eur Respir J

View full text Add to dashboard Cite

In the era of personalised cancer therapy, the demand for molecular profiling of the patient's tumour is steadily increasing. In advanced nonsmall cell lung cancer (NSCLC) patients, testing for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements has become an essential component of clinical practice to select patients who are most likely to benefit from EGFR and ALK tyrosine kinase inhibitors, respectively. Furthermore, obtaining tissue specimens from recurrent or metastatic tumours or from patients who develop resistance to initial effective therapies are essential for our understanding of the molecular basis of tumour progression and development of drug resistance. Therefore, the sampling of tumour tissue that is representative and is adequate in quantity and quality for pathological diagnosis and genomic profiling is crucial. In this review, we will discuss factors that should be considered in obtaining and processing biopsy specimens to enable routine molecular analysis in NSCLC patients. @ERSpublications Personalised therapy: adequate tumour tissue sampling for pathological diagnosis and molecular profiling is critical

show abstract

Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors

Cited by 9 publications

References 8 publications

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?

Contact Info

Product

Resources

About